by Aspirion | Aug 26, 2026 | Artificial Intelligence (AI), Denials Management, Legislation, Revenue Cycle Management
The insights and clinical expertise shared in this post and included in the Q2 2026 Payer Policy Playbook draw on the expertise of Autumn Resch, Supervisor, Denials, and Melony Malone Norwood, Senior Clinical Review Analyst. We are grateful for their dedication to...
by Aspirion | Aug 12, 2026 | Artificial Intelligence (AI), Denials Management, Revenue Cycle Management
The following recaps a Spark Session fireside chat delivered by Aspirion’s Chase McGrath, Vice President of Product, and Rikki Ashkin, JD, Senior Client Success Director, at the HFMA Region 8 Mid-America Summer Institute (MASI) in Des Moines, Iowa. The session...
by Aspirion | Aug 5, 2026 | Artificial Intelligence (AI), Denials Management, Revenue Cycle Management
If you’ve ever received a readmission denial and wondered, “How can the payer deny this when the patient clearly needed to be readmitted?” You’re not alone. Readmission denials are one of the most misunderstood areas of hospital billing and...
by Andrew Ficco | Jul 24, 2026 | Denials Management
Revenue Integrity ClinIQ The AI Powering Our Clinical Denials Intelligence Download Service Summary Aspirion's Services Meet ClinIQ Denials keep coming back—without clear insight into why. The solution. Our Denials Management experts use ClinIQ—our proprietary...
by Aspirion | Jul 15, 2026 | Artificial Intelligence (AI), Denials Management, Revenue Cycle Management
The denials environment isn’t getting easier for healthcare providers. Payers are faster, more automated, and better resourced than ever. Most hospital billing teams are working harder and recovering less. In revenue cycle management (RCM),...
by Aspirion | Jul 1, 2026 | Artificial Intelligence (AI), Denials Management, Revenue Cycle Management
Experimental and investigational denials are some of the most frustrating claim denials providers face. A procedure may be FDA approved, medically necessary, and even authorized, yet still denied as “experimental” or “non-covered.” In this...
